Chapter 9 : Tissue Responses and Special Topics in Immunity

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in

Tissue Responses and Special Topics in Immunity, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818241/9781555811075_Chap09-1.gif /docserver/preview/fulltext/10.1128/9781555818241/9781555811075_Chap09-2.gif


This chapter explores the host response to infection, with emphasis on integrating clinical observations with those from animal studies and in vitro observations. The chapter describes the host response to infection for lung, brain, and skin, since these are the organs for which most information is available. The inflammatory response to infection has four unusual features. First, the inflammatory response can range in intensity from florid, intense granulomatous inflammation to the virtual absence of inflammatory cells. The variables responsible for differences in the magnitude and intensity of the inflammatory response include the immune status of the host and poorly defined characteristics of strains. Second, can be found in tissue as both an intracellular pathogen and an extracellular pathogen. Third, the type of inflammatory response is a function, in part, of the organ tissue where the infection occurs. Fourth, there is considerable variation in the type of effector cells found in inflammatory responses. A study compared the inflammatory response to pulmonary infection in CBA/J mice using two strains of , and strongly suggested that some of the differences observed in the human inflammatory response may be the result of unique strain differences in host inflammatory cell recruitment. In summary, the literature strongly supports the view that impairment of cell-mediated immunity is associated with enhanced susceptibility to infection.

Citation: Casadevall A, Perfect J. 1998. Tissue Responses and Special Topics in Immunity, p 271-324. In . ASM Press, Washington, DC. doi: 10.1128/9781555818241.ch9

Key Concept Ranking

Major Histocompatibility Complex Class II
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1
Figure 1

Electron micrograph of -infected mouse lung tissue at day 7 of infection. The photomicrograph shows an area of lung with cryptococci filling the airspace, whereas other fungal cells are found in the intracellular space. Open arrows indicate extracellular cryptococci. Closed arrows indicate intracellular cryptococci. Most intracellular cryptococci are inside alveolar macrophages. The tissue comes from C57BL/6 mice, and the cryptococcal strain is ATCC 24067. For details of experimental infection and microscopy, see references and . Micrograph obtained at a magnification of ×3,000. Figure courtesy of Marta Feldmesser (Bronx, N.Y.).

Citation: Casadevall A, Perfect J. 1998. Tissue Responses and Special Topics in Immunity, p 271-324. In . ASM Press, Washington, DC. doi: 10.1128/9781555818241.ch9
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Temporal inflammatory changes in three organs following intracisternal infection in rats. Rats given infection thorough the intracisternal route controlled the infection and seldom died ( ). Histopathological sections of rat brain, lung, and spleen tissue on days 7, 15, and 30 after infection with are shown. (A) Brain tissue on day 7 reveals extracellular yeast forms (arrows) within the subarachnoid space. Original magnification, ×540. (B) Lung tissue on day 7 shows cryptococci surrounded by mononuclear cells. Original magnification, ×540. Cryptococci in lung tissue presumably are a result of hematogenous dissemination from brain tissue. (C) Spleen tissue on day 7 reveals no inflammation or cryptococci. Original magnification, ×335. (D) By day 15 the brain infection has changed histopathologically such that there are increased numbers of lymphocytes and macrophages in the subarachnoid space. Original magnification, ×335. (E) In the lung on day 15, inflammation has progressed to granuloma formation. Arrows point to cryptococci within Langerhans giant cells. Original magnification, ×335. (F) Spleen tissue on day 15 reveals discrete granulomas. Original magnification, ×335. (G) By day 30, inflammation has progressed in the subarachnoid space to include a large infiltration of lymphocytes, monocytes, and epithelioid cells. By this time, several layers of lymphocytes coat the pial surface. Original magnification, ×540. (H) In the lung on day 30, the inflammatory response continues with the formation of foamy macrophages. Original magnification, ×540. (I) In spleen tissue on day 30, inflammation is resolving, paralleling the resolution of infection in other organs. The figure, courtesy of David Goldman (Bronx, N.Y.), originally appeared in reference 94 and is reproduced here with permission.

Citation: Casadevall A, Perfect J. 1998. Tissue Responses and Special Topics in Immunity, p 271-324. In . ASM Press, Washington, DC. doi: 10.1128/9781555818241.ch9
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Amundson, D. E. 1992. Cavitary pulmonary cryptococcosis complicating Churg-Strauss vasculitis. South. Med. J. 85:700702.
2. Anderson, D. M.,, and M. A. Dykstra. 1984. Pulmonary cell response in mice following intranasal instillation with Cryptococcus neoformans. Mycopathologia 86:179184.
3. Aronson, M.,, and J. Kletter. 1973. Aspects of the defense against a large-sized parasite, the yeast, Cryptococcus neoformans. Isr. J. Med. Sci. 1:132162.
4. Asherton, G. L.,, V. Colizzi,, and M. Zembala. 1986. An overview of T-suppressor cell circuits. Annu. Rev. Immunol. 4:3768.
5. 4a. Atkinson, A. J.,, and J. E. B. Bennett 1968. Experience with a new skin test antigen prepared from Cryptococcus neoformans. Am. Rev. Respir. Dis. 97:637643.
5. Attal, H. C.,, S. Grover,, M. P. Bansai,, B. S. Chaubey,, and V. K. Joglekar. 1983. Capsule deficient Cryptococcus neoformans an unusual clinical presentation. J. Assoc. Physicians India 31:4951.
6. Baird, R. W.,, and A. S. Garfield. 1994. Cavitation and rupture of a pulmonary cryptococcoma in an immunocompetent man. Am. J. Med. 97:309311.
7. Baker, P. J. 1990. Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes. Infect. Immun. 58:34653468.
8. Baker, R. D. 1952. Resectable mycotic lesions and acutely fatal mycoses. JAMA 159:15791581.
9. Baker, R. D. 1976. The primary pulmonary lymph node complex of cryptococcosis. Am. J. Clin. Pathol. 65:8392.
10. Baker, R. D.,, and R. K. Haugen. 1955. Tissue changes and tissue diagnosis in cryptococcosis. A study of 26 cases. Am. J. Clin. Pathol. 25:1424.
11. Bennett, J. E.,, and H. F. Hasenclever. 1965. Cryptococcus neoformans polysaccharide: studies of serologic properties and role in infection. J. Immunol. 94:916920.
12. Bergman, F. 1961. Pathology ofexperimental cryptococcosis. A study of course and tissue response in subcutaneously inducedinfection in mice. Acta Pathol. Microbiol. Scand. 147(Suppl.):l163.
13. Berk, M.,, and B. Gerstl. 1952. Torulosis (Cryptococcosis) producing a solitary pulmonary lesion. JAMA 149:13101312.
14. Bird, D. C.,, J. N. Sheagren,, and J. E. Bennett 1969. Reticuloendothelial phagocytic function during systemic mycotic infections in man. J. Lab. Clin. Med. 74:340345.
15. Blackstock, R. 1996. Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J. Med. Vet. Mycol. 34:1930.
16. Blackstock, R.,, and A. Casadevall. 1997. Presentation of cryptococcal capsular polysaccharide (GXM) on activated antigen presenting cells inhibits the T-suppressor response and enhances delayed-type hypersensitivity and survival. Immunology 92:334339.
17. Blackstock, R.,, and N. K. Hall. 1982. Immunosuppression by avirulent, pseudohyphal forms of Cryptococcus neoformans. Mycopathologia 80:9599.
18. Blackstock, R.,, and N. K. Hall. 1984. Non-specific immunosuppression by Cryptococcus neoformans infection. Mycopathologia 86:3543.
19. Blackstock, R.,, N. K. Hall,, and N. C. Hernandez. 1989. Characterization of a suppressor factor that regulates phagocytosis by macrophages in murine cryptococcosis. Infect. Immun. 57:17731779.
20. Blackstock, R.,, and N. C. Hernandez. 1988. Inhibition of macrophage phagocytosis in cryptococcosis: phenotypic analysis of the suppressor cell. Cell. Immunol. 114:174187.
21. Blackstock, R.,, and N. C. Hernandez. 1989. Characterization of the macrophage subset affected and its response to a T suppressor factor (TsFmp) found in cryptococcosis. Infect. Immun. 57:29312937.
22. Blackstock, R.,, J. M. McCormack,, and N. K. Hall. 1987. Induction of a macrophage-suppressive lymphokine by soluble cryptococcal antigens and its association with models of immunologic tolerance. Infect. Immun. 55:233239.
23. Blackstock, R.,, M. Zembala,, and G. L. Asherson. 1991. Functional equivalence of cryptococcal and haptene-specific T suppressor factor (TsF). I. Picryl and oxazolone-specific TsF, which inhibit transfer of contact sensitivity, also inhibit phagocytosis by a subset of macrophages. Cell. Immunol. 136:435447.
24. Blackstock, R.,, M. Zembala,, and G. L. Asherson. 1991. Functional equivalence of cryptococcal and haptene-specific T suppressor factor (TsF). II. Monoclonal anti-cryptococcal TsF inhibits both phagocytosis by a subset of macrophages and transfer of contact sensitivity. Cell. Immunol. 136:448461.
25. Blasi, E.,, R. Barluzzi,, R. Mazzola,, F. Mosci,, and F. Bistoni. 1992. Experimental model of intracerebral infection with Cryptococcus neoformans: roles of phagocytes and opsonization. Infect. Immun. 60:36823688.
26. Blasi, E.,, R. Barluzzi,, R. Mazzola,, L. Pitzurra,, M. Puliti,, S. Saleppico,, and F. Bistoni. 1995. Biomolecular events involved in anticryptococcal resistance in the brain. Infect. Immun. 63:12181222.
27. Blasi, E.,, R. Mazzola,, R. Barluzzi,, P. Mosci,, A. Bartoli,, and F. Bistoni. 1991. Intracerebral transfer of an in vitro established microglial cell line: local induction of a protective state against lethal challenge with Candida albicans. J. Neuroimmunol. 32:249257.
28. Blasi, E.,, R. Mazzola,, R. Barluzzi,, P. Mosci,, and F. Bistoni. 1994. Anticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells. Infect. Immun. 62:31893196.
29. Brajtburg, J.,, W. G. Powderly,, G. Kobayashi,, and G. Medoff. 1993. Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34:183188.
30. Brodie, S. J.,, V. G. Sasseville,, K. A. Reinmann,, M. A. Simon,, P. K. Sehgal,, and D. J. Ringler. 1994. Macrophage function in simian AIDS. Killing defects in vivo are independent of macrophage function, associated with alterations in Th phenotype, and reversible with IFN-gamma. J. Immunol. 153:5790.
31. Brueske, C. H. 1986. Proteolytic activity of a clinical isolate of Cryptococcus neoformans. J. Clin. Microbiol. 23:631633.
32. Brummer, E.,, and D. A. Stevens. 1994. Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: synergy with fluconazole for killing. J. Infect. Dis. 170:173179.
33. Buchanan, K. L.,, P. L. Fidel,, and J. W. Murphy. 1991. Effects of Cryptococcus neoformans-specific suppressor T cells on the amplified anticryptococcal delayed-type hypersensitivity response. Infect. Immun. 59:2935.
34. Bulmer, G. S.,, and J. R. Tacker. 1975. Phagocytosis of Cryptococcus neoformans by alveolar macrophages. Infect. Immun. 11:7379.
35. Cameron, M. L.,, J. A. Bartlett,, H. A. Gallis,, and H. A. Waskin. 1991. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev. Infect. Dis. 13:6467.
36. Cameron, M. L.,, D. L. Granger,, T. J. Matthews,, and J. B. Weinberg. 1994. Human immunodeficiency virus (HIV)-infected human blood monocytes and peritoneal macrophages have reduced anticryptococcal activity whereas HIV-infected alveolar macraphages retain normal activity. J. Infect. Dis. 170:6070.
37. Carton, C. A.,, and L. A. Mount. 1951. Neurosurgical aspects of cryptococcosis. J. Neurosurg. 8:143156.
38. Casadevall, A. 1993. Cryptococcosis: the case for immunotherapy. Cliniguide to Fungal Infections 4:15.
39. Casadevall, A.,, D. L. Goldman,, and M. Feldmesser. 1997. Antibody-based therapies for infectious diseases: renaissance for an abandoned arsenal? Bull. Inst. Pasteur 95:247257.
40. Casadevall, A.,, J. Mukherjee,, Y. RuiRong,, and J. Perfect. 1994. Management of Cryptococcus neoformans contaminated needle injuries. Clin. Infect. Dis. 19:951953.
41. Cauley, L. K.,, and J. W. Murphy. 1979. Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect. Immun. 23:644651.
42. Cawley, E. P.,, R. H. Grekin,, and A. C. Curtis. 1950. Torulosis. A review of the cutaneous and adjoining mucous membrane manifestations. J. Invest Dermatol. 14:327344.
43. Chatuverdi, V.,, B. Wong,, and S. L. Newman. 1996. Oxidative killing of Cryptococcus neoformans by human leukocytes. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. J. Immunol. 156:38363840.
44. Chen, L. -C.,, E. Blank,, and A. Casadevall. 1996. Extracellular proteinase activity of Cryptococcus neoformans. Clin. Diagn. Lab. Immunol. 3:570574.
45. Cherniak, R.,, and J. B. Sundstrom. 1994. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect. Immun. 62:15071512.
46. Clemons, K. V.,, R. Azzi,, and D. A. Stevens. 1996. Experimental systemic cryptococcosis in SCID mice. J. Med. Vet. Mycol. 34:331335.
47. Clemons, K. V.,, E. Drummer,, and D. A. Stevens. 1994. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob. Agents Chemother. 38:460464.
49. Collins, H. L.,, and G. J. Bancroft. 1991. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect. Immun. 59:38833888.
50. Curtis, J. L.,, G. B. Huffnagle,, G. H. Chen,, M. L. Warnock,, M. Gyetko,, R. McDonald,, P. Scott,, and G. B. Toews. 1994. Experimental murine pulmonary cryptococcosis. Lab. Invest. 71:113126.
51. Cusini, M.,, P. Cagliani,, R. Grimalt,, G. Tadini,, E. Alessi,, and M. Fasan. 1991. Primary cutaneous cryptococcosis in a patient with the Acquired Immunodeficiency Syndrome. Arch. Dermatol. 127:18481849.
52. Daniel, P. M.,, F. Shiller,, and R. L. Vollum. 1949. Torulosis of the central nervous system. Report of two cases. Lancet i:5356.
53. DeShaw, M.,, and L.-A. Pirofski. 1995. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV— individuals. Clin. Exp. Immunol. 99:425432.
54. Diamond, R. D. 1977. Effects of stimulation and suppression of cell-mediated immunity on experimental cryptococcosis. Infect. Immun. 17:187194.
55. Diamond, R. D.,, and J. E. Bennett. 1973. Disseminated cryptococcosis in man: decreased lymphocyte transformation in response to Cryptococcus neoformans. J. Infect. Dis. 127:694697.
56. Diamond, R.D.,, and J. E. Bennett 1973. Growth of Cryptococcus neoformans within human macrophages in vitro. Infect. Immun. 7:2312360.
57. Diamond, R. D.,, and N. F. Erickson III. 1982. Chemotaxis of human neutrophils and monocytes induced by Cryptococcus neoformans. Infect. Immun. 38:380382.
58. Diamond, R. D.,, J. E. May,, M. Kane,, M. M. Frank,, and J. E. Bennett 1973. The role of late complement component and the alternate complement pathway in experimental cryptococcosis (37580). Proc. Soc. Exp. Biol. Med. 144:312315.
59. Diamond, R. D.,, J. E. May,, M. C. Kane,, M. M. Frank,, and J. E. Bennett 1974. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J. Immunol. 112:22602270.
60. Dixon, D. M.,, and A. Polak. 1986. In vivo and in vitro studies with an atypical, rhinotrophic isolate of Cryptococcus neoformans. Mycopathologia 96:3340.
61. Dobiick, P.,, K. Miksits,, and H. Hahn. 1995. L3T4(CD4)-, Lyt-2(CD8)- and Mac-1(CD11b)-phenotypic leukocytes in murine cryptococcal meningoencephalitis. Mycopathologia 131:159166.
62. Dong, Z. M.,, and J. W. Murphy. 1993. Mobility of human neutrophils in response to Cryptococcus neoformans cells, culture filtrate antigen, and individual components of the antigen. Infect. Immun. 61:50675077.
63. Dong, Z. M.,, and J. W. Murphy. 1995. Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect. Immun. 63:770778.
64. Dong, Z. M.,, and J. W. Murphy. 1995. Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect. Immun. 63:26322644.
65. Dong, Z. M.,, and J. W. Murphy. 1996. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis receptor loss from the surface of human neutrophils. J. Clin. Invest. 97:689698.
66. Dong, Z. M.,, and J. W. Murphy. 1997. Cryptococcal polysaccharide bind to CD18 on human neutrophils. Infect. Immun. 65:557563.
67. Dorf, M.,, and B. Benacerraf. 1984. Suppressor cells and immunoregulation. Annu. Rev. Immunol. 2:127158.
68. Dormer, B. A.,, J. Friedlander,, F. J. Wiles,, and F. W. Simson. 1945. Tumor of the lung due to Cryptococcus histolyticus (blastomycosis). J. Thoracic Surg. 14:322329.
69. Dromer, E.,, and J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 163:11141120.
70. Drouhet, E.,, and G. Segretain. 1951. Inhibition de la migration leucocytaire in vitro par un polyoside capsulaire de Torulopsis (Cryptococcus) neoformans. Ann. Inst. Pasteur 81:674.
71. Duke, S. S.,, and R. A. Fromtling. 1984. Effects of diethylstilbestrol and cyclophosphamide on the pathogenesis of experimental Cryptococcus neoformans infections. J. Med. Vet. Mycol. 22:125135.
72. Durden, F. M.,, and B. Elewski. 1994. Cutaneous involvement with Cryptococcus neoformans in AIDS. J. Am. Acad. Dermatol. 30:844848.
73. Dystra, M. A.,, and L. Friedman. 1978. Pathogenesis, lethality, and immunizing effect of experimental cutaneous cryptococcosis. Infect. Immun. 20:446455.
74. Epstein, R.,, R. Cole, and K. K. Hunt. 1972. Pleural effusion secondary to pulmonary cryptococcosis. Chest 61:296298.
75. Farmer, S. G.,, and R. A. Komorowski. 1973. Histologic response to capsule-deficient Cryptococcus neoformans. Arch. Pathol. 96:383387.
76. Feldmesser, M.,, and A. Casadevall. 1997. Effect of serum IgG1 against murine pulmonary infection with Cryptococcus neoformans. J. Immunol. 158:790799.
77. Feldmesser, M.,, A. Casadevall,, Y. Kress,, G. Spira,, and A. Orlofski. 1997. Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro. Infect. Immun. 65:18991907.
78. Feldmesser, M.,, J. Mukherjee,, and A. Casadevall. 1996. Combination of 5-flucytosine and capsule binding monoclonal antibody in therapy of murine Cryptococcus neoformans infections and in vitro. J. Antimicrob. Chemother. 37:617622.
79. Ferry, J. A.,, C. K. Pettit,, A. E. Rosenberg,, and N. L. Harris. 1991. Fungi in megakaryocytes. An unusual manisfestation of fungal infection in the bone marrow. Am. J. Clin. Pathol. 96:577581.
80. Fidel, P. L.,, and J. W. Murphy. 1988. Characterization of an in vitro-stimulated, Cryptococcus neoformans-specific second-order suppressor T cell and its precursor. Infect. Immun. 56:12671272.
81. Freeman, W. 1930. Torula meningo-encephalitis. Comparative histopathology in seventeen cases. Trans. Am. Neurol. Assoc. 56:203217.
82. Freeman, W. 1931. Torula infection of the central nervous system. J. Psychol. Neurol. 43:236245.
83. Friedman, E. P.,, R. F. Miller,, A. Severn,, I. G. Williams,, and P. J. Shaw. 1995. Cryptococcal pneumonia in patients with the acquired immunodeficiency syndrome. Clin. Radiol. 50:756760.
84. Frisch, M.,, and D. R. Gnepp. 1995. Primary cryptococcal infection of the larynx: report of a case. Otolaryngol. Head Neck Surg. 113:477480.
85. Fromtling, R. A.,, G. K. Abruzzo,, and A. Ruiz. 1988. Cryptococcus neoformans: a central nervous system isolate from an AIDS patient that is rhinotropic in a normal mouse model. Mycopathologia 102:7986.
86. Fromtling, R. A.,, and H. J. Shadomy. 1982. Immunity in cryptococcosis: an overview. Mycopathologia 77:183190.
87. Gadebusch, H. H. 1961. Natural host resistance to infection with Cryptococcus neoformans. The effect of the properdin system on the experimental disease. J. Infect. Dis. 109:147153.
88. Gadebusch, H. H. 1972. Mechanisms of native and acquired resistance to infection with Cryptococcus neoformans. Crit. Rev. Microbiol 1:311320.
89. Gal, A. A.,, M. N. Koss,, J. Hawkins,, S. Evans,, and H. Einstein. 1986. The pathology of pulmonary cryptococcal infections in the acquired immunodeficiency syndrome. Arch. Pathol. Lab. Med. 110:502507.
90. Ghigliotti, G.,, G. Carrega,, A. Farris,, A. Burroni,, A. Nigra,, G. Pagano,, and R. De Marchi. 1992. Cutaneous cryptococcosis resembling molluscum contagiosum in a homosexual man with AIDS. Acta Dermatol. Venereol. 72:182184.
91. Glaser, J. B.,, and A. Garden. 1985. Inoculation of cryptococcosis without transmission of the acquired immunodeficiency syndrome. N. Engl J. Med. 313:266.
92. Goldman, D.,, Y. Cho,, M.-L. Zhao,, A. Casadevall,, and S. C. Lee. 1996. Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. Am. J. Pathol. 148:12751282.
93. Goldman, D.,, S. C. Lee,, and A. Casadevall. 1994. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect. Immun. 62:47554761.
94. Goldman, D. L.,, A. Casadevall,, Y. Cho,, and S. C. Lee. 1996. Cryptococcus neoformans meningitis in the rat. Lab. Invest. 75:759770.
95. Goodman, J. S.,, L. Kaufman,, and G. Koenig. 1971. Diagnosis of cryptococcal meningitis. N. Engl. J. Med. 285:434436.
96. Gordon, M. A.,, and A. Casadevall. 1995. Serum therapy of cryptococcal meningitis. Clin. Infect. Dis. 21:14771479.
97. Gordon, M. A.,, and E. Lapa. 1964. Serum protein enhancement of antibiotic therapy in cryptococcosis. J. Infect. Dis. 114:373378.
98. Gordon, S. M.,, A. A. Gal,, and J. R. Amerson. 1994. Granulomatous peritoneal cryptococcomas. An unusual sequela of disseminated cryptococcosis. Arch. Pathol. Lab. Med. 118:194195.
99. Graybill, J. R.,, J. Ahrens,, T. Nealon,, and R. Paque. 1983. Pulmonary cryptococcosis in the rat. Am. Rev. Respir. Dis. 127:636640.
100. Graybill, J. R.,, and R. H. Alford. 1974. Cell-mediated immunity in cryptococcosis. Cell. Immunol. 14:1221.
101. Graybill, J. R.,, R. Bocanegra,, C. Lambros,, and M. F. Luther. 1997. Granulocyte colony stimulating factor therapy of experimental cryptococcal meningitis. J. Med. Vet. Mycol. 35:243247.
102. Graybill, J. R.,, and D. J. Drutz. 1978. Host defense in cryptococcosis. II. Cryptococcosis in the nude mouse. Cell. Immunol. 40:263274.
103. Griffin, F. M. 1980. Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptococcus neoformans. Proc. Natl Acad. Sci. USA 78:38533857.
104. Gutierrez, F.,, Y. S. Fu,, and H. I. Lurie. 1975. Cryptococcosis histologically resembling histoplasmosis. Arch. Pathol 99:347353.
105. Gyetko, M. R.,, G.-H. Chen,, R. A. McDonald,, R. Goodman,, G. B. Huffnagle,, C. C. Wilkinson,, J. A. Fuller,, and G. B. Toews. 1996. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. J. Clin. Invest. 97:18181826.
106. Harrison, T. S.,, H. Kornfeld,, and S. M. Levitz. 1995. The effect of infection with human immunodeficiency virus on the anticryptococcal activity of lymphocytes and monocytes. J. Infect. Dis. 172:665671.
107. Haugen, R. K.,, and R. D. Baker. 1954. The pulmonary lesions in cryptococcosis with special reference to subpleural nodules. Am. J. Clin. Pathol. 24:13811390.
108. Heere, L. J.,, T. A. Mahvi,, and M. M. Annable. 1975. Effect of temperature on growth and macromolecular biosynthesis in Cryptococcus species. Mycopathologia 55:105113.
109. Henderson, D. K.,, J. E. Bennett,, and M. A. Huben 1982. Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis. J. Clin. Invest. 69:11851190.
110. Henderson, D.K.,, V. L. Kan,, and J. E. Bennett. 1986. Tolerance to cryptococcal polysaccharide in cured cryptococcosis patients: failure of antibody secretion in vitro. Clin. Exp. Immunol. 65:639646.
112. Hill, J. 0.1992. CD4+ T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J. Exp. Med. 175:16851695.
113. Hill, J. O.,, and K. M. Aguirre. 1994. CD4+ T cell-dependent acquired state of immunity that protects the brain against Cryptococcus neoformans. J. Immunol. 152:23442350.
114. Hill, J. O.,, and R L. Dunn. 1993. A T cell-independent protective response against Cryptococcus neoformans expressed at the primary site of infection in the lung. Infect. Immun. 61:53025308.
115. Hino, H.,, K. Takizawa,, and G. Asboe-Hansen. 1982. Ultrastmcture of Cryptococcus neoformans. Acta Dermatol. Venereol. 62:113117.
116. Hinrichs, J.,, D. Kitz,, G. Kobayashi,, and J. R. Little. 1983. Immune enhancement in mice by Ara-A. J. Immunol. 130:829833.
117. Hirano, A.,, H. M. Zimmerman,, and S. Levine. 1964. Fine structure of cerebral fluid accumulation. V. Transfer of fluid from extracellular compartments in acute phase of cryptococcal polysaccharide lesions. Arch. Neurol. 11:632641.
118. Hirano, A.,, H. M. Zimmerman,, and S. Levine. 1964. Fine structure of cerebral fluid accumulation. III. Extracellular spread of cryptococcal polysaccharides in the acute stage. Am. J. Pathol. 46:111.
119. Hirano, A.,, H. M. Zimmerman,, and S. Levine. 1965. Fine structure of cerebral fluid accumulation. VI. Intracellular accumulation of fluid and cryptococcal polysaccharide in oligodendria. Arch. Neurol. 12:189196.
120. Hirano, A.,, H. M. Zimmerman,, and S. Levine. 1965. Fine structure of cerebral fluid accumulation. VII. Reactions of astrocytes to cryptococcal polysaccharide implantation. J. Neuropathol. Exp. Neurol. 24:386396.
121. Hobbs, M. M.,, J. R. Perfect,, D. L. Granger,, and D. T. Durack. 1990. Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Infect. Immun. 58:21152119.
122. Hoff, C. L. 1942. Immunity studies of Cryptococcus hominis (Torula histolytica) in mice. J. Lab. Clin. Med. 27:751754.
123. Horn, C. A.,, and R. G. Washburn. 1995. Anticryptococcal activity of NK cell-enriched peripheral blood lymphocytes from human immunodeficiency virus-infected subjects: responses to interleukin-2, interferon-gamma, and interleukin-12. J. Infect. Dis. 172:10231027.
124. Huffnagle, G. B.,, G.-H. Chen,, J. L. Curtis,, R. A. McDonald,, R. M. Strieter,, and G. B. Toews. 1995. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J. Immunol. 155:35073516.
125. Huffnagle, G. B.,, and M. F. Lipscomb. 1992. Animal model of human disease: pulmonary cryptococcosis. Am. J. Pathol. 141:15171520.
126. Huffnagle, G.B.,, M. F. Lipscomb,, J. A. Lovchik,, K. A. Hoag,, and N. E. Street. 1994. The role of CD4+ and CD8+ T-cells in protective inflammatory response to a pulmonary cryptococcal infection. J. Leukocyte Biol 55:3542.
127. Huffnagle, G. B.,, N. E. Street,, and M. Lipscomb. 1992. In contrast to Balb/c mice, a Cryptococcus neoformans infection in C57BL/6 mice generates protective T cell immunity in the periphery and non-protective T-cell mediated eosinophilia in the lungs. FASEB J. 6:A1689. (Abstract.)
128. Huffnagle, G. B.,, R. M. Strieter,, T. J. Standiford,, R. A. McDonald,, M. D. Burdick,, S. L. Kunkel,, and G. B. Toews. 1995. The role of monocyte chemotactic protein-1 (MCP-1) in the recruitment of monocytes and CD4+ T cells during a pulmonary Cryptococcus neoformans infection. J. Immunol. 155:47904797.
129. Huffnagle, G. B.,, J. L. Yates,, and M. F. Lipscomb. 1991. T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SOD and athymic nude mice. Infect. Immun. 59:14231433.
130. Huffnagle, G. B.,, J. L. Yates,, and M. F. Lipscomb. 1991. Immunity to pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J. Exp. Med. 173:793800.
131. Iarobellis, F. W.,, M. I. Jacobs,, and R. P. Cohen. 1984. Primary cutaneous cryptococcosis. Arch. Dermatol. 23:673675.
132. Jacobson, E.S.,, and S. B. TinnelL1993. Antioxidant function of fungal melanin. J. Bacteriol. 175:71027104.
133. Joly, V.,, L. Saint-Julien,, C. Carbon,, and P. Yeni. 1994. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J. Infect. Dis. 170:13311334.
134. Kagaya, K.,, T. Yamada,, Y. Miyakawa,, Y. Fukazawa,, and S. Saito. 1985. Characterization of pathogenic constituents of Cryptococcus neoformans strains. Microbiol. Immunol. 29:517532.
135. Kahn, F. W.,, D. N. England,, and J. M. Jones. 1985. Solitary pulmonary nodule due to Cryptococcus neoformans and Mycobacterium tuberculosis. Am. J. Med. 78:677681.
136. Kalina, M.,, Y. Kletter,, and M. Aronson. 1974. The interaction of phagocytes and the large-sized parasite Cryptococcus neoformans: cytochemical and ultrastructural study. Cell Tissue Res. 152:165174.
137. Kawakami, K.,, S. Kohno,, J. -I. Kadota,, M. Tohyama,, K. Teruya,, N. Kedeken,, A. Saito,, and K. Hara. 1995. T cell-dependent activation of macrophages and enhancement of their phagocytic activity in the lungs of mice inoculated with heat-killed Cryptococcus neoformans: involvement of IFN-gamma and its protective effect against cryptococcal infection. Microbiol. Immunol. 39:135143.
138. Kawakami, K.,, S. Kohno,, N. Morikawa,, J. Kadota,, A. Saito,, and K. Hara. 1994. Activation of macrophages and expansion of specific T lymphocytes in the lungs of mice intratracheally inoculated with Cryptococcus neoformans. Clin. Exp. Immunol. 96:230237.
139. Kent T. H.,, and J. M. Layton. 1962. Massive pulmonary cryptococcosis. Am. J. Clin. Pathol. 38:596604.
140. Kerkering, T. M.,, R. J. Duma,, and S. Shadomy. 1981. The evolution of pulmonary cryptococcosis. Ann. Intern. Med. 94:611616.
141. Kessel, J. E.,, and F. Holtzwart. 1935. Experimental studies with torula from a knee infection in man. Am. J. Trop. Med. 15:467481.
142. Khakpour, F. R.,, and J. W. Murphy. 1987. Characterization of a third-order suppressor T cell (Ts3) induced by cryptococcal antigen. Infect. Immun. 55:16571662.
143. Kitchen, L. W. 1996. Adjunctive immunologic therapy for Cryptococcus neoformans infections. Clin. Infect. Dis. 23:209210.
144. Kitchen, L. W.,, J. A. Ross,, J. E. Hernandez,, A. L. Zarraga,, and F. J. Mather. 1992. Effect of administration of diethylcarbamazine on experimental bacterial and fungal infections in mice. Int. J. Antimicrob. Agents 1:259268.
145. Kitchen, L. W.,, J. A. Ross,, B. S. Turner,, J. E. Hernandez,, and F. J. Mather. 1995. Diethylcarbamazine enhances blood microbicidal activity. Adv. Therapy 12:2229.
146. Kobayashi, T.,, I. Nakashima,, and N. Kato. 1975. Factors affecting experimental infection with Cryptococcus neoformans in mice with special reference to an endotoxic substance of C. neoformans. Mycopathologia 55:1722.
147. Kozel, T. R. 1993. Opsonization and phagocytosis of Cryptococcus neoformans. Arch. Med. Res. 24:211218.
148. Kozel, T. R. 1996. Activation of the complement system by pathogenic fungi. Clin. Microbiol. Rev. 9:3446.
149. Kozel, T. R.,, and J. Cazin, Jr. 1972. Immune response to Cryptococcus neoformans soluble polysaccharide. Infect. Immun. 5:3541.
150. Kozel, T. R.,, and E. Gotschlich. 1982. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol. 129:16751680.
151. Kozel, T. R.,, W. F. Gulley,, and J. Cazin, Jr. 1977. Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect. Immun. 18:701707.
152. Kozel, T. R.,, and G. S. T. Pfrommer. 1986. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect. Immun. 52:15.
153. Kozel, T. R.,, E. Reiss,, and R. Cherniak. 1980. Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide. Infect. Immun. 29:295300.
154. Krainer, L.,, J. M. Small,, A. B. Hewlitt,, and T. Deness. 1946. A case of systemic torula infection with tumour formation in the meninges. J. Neurol. Neurosurg. Psychiatr. 9:158162.
155. Kuhn, L. R. 1939. Experimental cryptococcic infection. Arch. Pathol. 27:803.
156. Laxalt, K. A.,, and T. R. Kozel. 1979. Chemotoxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans. Infect. Immun. 26:435440.
157. Lee, S. C.,, and A. Casadevall. 1996. Polysaccharide antigen in brain tissue of AIDS patients with cryptococcal meningitis. Clin. Infect. Dis. 23:194195.
158. Lee, S. C.,, A. Casadevall,, and D. W. Dickson. 1996. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am.J. Pathol. 148:12671274.
159. Lee, S. C.,, D. W. Dickson,, and A. Casadevall. 1996. Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum. Pathol. 27:839847.
161. Lee, S. L.,, Y. Kress,, M.-L. Zhao,, D. W. Dickson,, and A. Casadevall. 1995. Cryptococcus neoformans survive and replicate in spacious phagosomes in human microglia. Lab. Invest. 73:871879.
162. Lehrer, R. I.,, A. K. Lichenstein,, and T. Ganz. 1993. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu. Rev. Immunol. 11:105128.
163. Levine, S.,, H. M. Zimmerman,, and A. Scorza. 1957. Experimental cryptococcosis (torulosis). Am. J. Pathol. 33:385409.
164. Levitz, S. M. 1992. Overview of host defenses in fungal infections. Clin. Infect. Dis. 14(Suppl. 1):S37BS42.
165. Levitz, S. M.,, and T. P. Farrell. 1990. Growth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface and cytokines. Infect. Immun. 58:12011209.
166. Levitz, S.M.,, A. Tabumi,, H. Komfeld,, C. C. Reardon,, and D. T. Golenbock. 1994. Production of tumornecrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect. Immun. 62:19751981.
167. Levitz, S. M.,, A. Tabuni,, and C. Treseler. 1993. Effect of mannose-binding protein on binding of Cryptococcus neoformans to human phagocytes. Infect. Immun. 61:48914893.
168. Ley, A.,, R. Jacas,, and C. Oliveras. 1951. Torula granuloma of the cervical spinal cord. J. Neurosurg. 8:327335.
169. Lim, T. S.,, J. W. Murphy,, and L. K. Cauley. 1980. Host-etiological agent interactions in intranasally and intraperitoneally induced cryptococcosis in mice. Infect. Immun. 29:633641.
170. Linell, F.,, B. Magnusson,, and A. Norden. 1953. Cryptococcosis. Review and report of a case. Acta Dermatol. Venereol. 33:103122.
171. Lipscomb, M. F. 1989. Lung defenses against opportunistic infections. Chest 96:13931399.
172. Lipscomb, M. F.,, G. B. Huffnagle,, J. A. Lovchik,, C. R. Lyons,, A. M. Pollard,, and J. L. Yates. 1993. The role of T lymphocytes in pulmonary microbial defense mechanisms. Arch. Pathol. Lab. Med. 117:12251232.
172a. Liu, C. T. 1953. Intracerebral cryptococdc granuloma. J. Neurosurg. 10:686689.
173. Louie, A.,, A. L. Baltch,, M. A. Franke,, R. P. Smith,, and M. A. Gordon. 1994. Comparative efficacy of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J. Antimicrob. Chemother. 34:975987.
174. Lovchik, J.A.,, and M. F. Lipscomb. 1993. Role for C5 and neutrophils in the pulmonary intravascular clearance of circulating Cryptococcus neoformans. Am. J. Respir. Cell. Mol. Biol. 9:617627.
175. Lovchik, J.A.,, C. R. Lyons,, and M. F. Lipscomb. 1995. A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am.J. Respir. Cell. Mol. Biol. 13:116124.
176. Love, G.L.,, G. D. Boyd,, and D. L. Green 1985. Large Cryptococcusneoformans isolated from brain abscess. J. Clin.Microbiol. 22:10681070.
177. Lurie, H. L.,, and H. J. Shadomy. 1971. Morphological variations of a hypha-forrning strain of Cryptococcus neoformans (Coward strain) in tissues of mice. Sabouraudia 9:1014.
178. Macher, A., M. J. E. Bennett,, J. E. Gadek,, and M. M. Frank. 1978. Complement depletion in cryptococcal sepsis. J. Immunol. 120:16861690.
179. Manfredi, R.,, A. Mazzoni,, A. Nanetti,, A. Mastroianni,, O. Coronado,, and F. Chiodo. 1996. Morphologic features and clinical significance of skin involvement in patients with AIDS-related cryptococcosis. Acta Dermatol. Venereol. 76:7276.
180. Manrique, P.,, J. Mayo,, J. A. Alvarez,, X. Ganchegui,, I. Zabalza,, and M. Flores. 1992. Polymorphous cutaneous cryptococcosis: nodular, herpes-like, and molluscum-like lesions in a patient with the acquired immunodeficiency syndrome. J. Am. Acad. Dermatol. 26:122124.
181. Marquis, G.,, S. Montplaisir,, M. Pelletier,, S. Mousseau,, and P. Auger. 1985. Genetic resistance to murine cryptococcosis: increased susceptibility in the CBA/N XID mutant strain of mice. Infect. Immun. 47:282287.
182. Martinez, A. J.,, M. Sell,, T. Mitrovics,, G. Stoltenburg-Didinger,, J. R. Iglesias-Rozas,, M. A. Giraldo-Velasquez,, G. Gosztonyi,, V. Schneider,, and J. Cervos-Navarro. 1995. The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases. Pathol. Res. Pract. 191:427443.
183. Masih, D. T.,, C. E. Sotomayor,, L. A. Cervi,, C. M. Riera,, and H. R. Rubinstein. 1991. Inhibition of I-A expression in rat peritoneal macrophages due to T-suppressor cells induced by Cryptococcus neoformans. J. Med. Vet. Mycol. 29:125128.
184. Masih, D. T.,, C. E. Sotomayor,, H. R. Rubinstein,, and C. M. Riera. 1991. Immunosuppression in experimental cryptococcosis in rats. Induction of efferent T suppressor cells to a non-related antigen. Mycopathologia 114:179186.
185. Mazzola, R.,, R. Barluzzi,, A. Brozzetti,, J. R. Boelaert,, T. Luna,, S. Saleppico,, F. Bistoni,, and E. Blasi. 1997. Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis. Antimicrob. Agents Chemother. 41:802807.
186. McDonnell, J. M.,, and G. M. Hutchins. 1985. Pulmonary cryptococcosis. Hum. Pathol. 16:121128.
187. Megson, G. M.,, D. A. Stevens,, J. R. Hamilton,, and D. W. Denning. 1996. D-Mannitol in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis. J. Clin. Microbiol. 34:218221.
187a. Meighan, J. W. 1972. Pulmonary cryptococcosis mimicking carcinoma of the lung. Radiology 103:6162.
188. Meyohas, M.-G.,, P. Roux,, D. Bollens,, C. Chouaid,, W. Rozenbaum,, J.-L. Meynard,, J.-L. Poirot,, J. Frottier,, and C. Mayaud. 1995. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin. Infect. Dis. 21:628633.
189. Miller, G. P. G. 1986. The immunology of cryptococcal disease. Semin. Respir. Infect. 1:4552.
190. Miyaji, M.,, and K. Nishimura. 1981. Studies on organ specificity in experimental murine cryptococcosis. Mycopathologia 76:145154.
191. Mody, C. H.,, G.-H. Chen,, C. Jackson,, J. L. Curtis,, and G. B. Toews. 1993. Depletion of murine CD8+ T-cells in vivo decreases pulmonary clearance of a moderately virulent strain of Cryptococcus neoformans. J. Lab. Clin. Med. 121:765773.
192. Mody, C. H.,, and R. M. Syme. 1993. Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans. Infect. Immun. 61:464469.
193. Mook, W. H.,, and M. Moore. 1936. Cutaneous torulosis. Arch. Dermatol. Syph. 33:951962.
194. Morgan, M. A.,, R. A. Blackstock,, G. S. Bulmer,, and N. K. Hall. 1983. Modification of macrophage phagocytosis in murine cryptococcosis. Infect. Immun. 40:493500.
195. Moser, S. A.,, F. L. Lyon,, J. E. Domer,, and J. E. Williams. 1982. Immunization of mice by intracutaneous inoculation with viable virulent Cryptococcus neoformans: immunological and histopathological parameters. Infect. Immun. 35:685696.
196. Mosley, R. L.,, J. W. Murphy,, and R. A. Cox. 1986. Immunoadsorption of Cryptococcus-specific suppressor T-cell factors. Infect. Immun. 51:844850.
197. Mukherjee, J.,, M. Feldmesser,, M. D. Scharff,, and A. Casadevall. 1995. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole activity. Antimicrob. Agents Chemother. 39:13981405.
198. Mukherjee, J.,, L. Pirofski,, M. D. Scharff,, and A. Casadevall. 1993. Antibody mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl. Acad. Sci. USA 90:36363640.
199. Mukherjee, J.,, L. Zuckier,, M. D. Scharff,, and A. Casadevall. 1994. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chemother. 38:580587.
200. Mukherjee, S.,, S. Lee,, J. Mukherjee,, M. D. Scharff,, and A. Casadevall. 1994. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect. Immun. 62:10791088.
201. Mulanovich, V. E.,, W. E. Dismukes,, and N. Markowitz. 1995. Cryptococcal empyema: case report and review. Clin. Infect. Dis. 20:13961398.
202. Muller, W.,, W. Schorre,, R. Suchenwirth,, H. M. Zitz,, and G. Konorza. 1978. A case of fatal cryptococcus meningitis with intracerebral granuloma. Acta Neurochirur. 44:223235.
203. Murakawa, G. J.,, R. Kerschmann,, and T. Berger. 1996. Cutaneous Cryptococcus infection and AIDS. Arch. Dermatol. 132:545548.
204. Murphy, J. W. 1985. Effects of first-order Cryptococcus-specific T-suppressor cells on induction of cells responsible for delayed-type hypersensitivity. Infect. Immun. 48:439445.
205. Murphy, J. W. 1988. Influence of cryptococcal antigens on cell-mediated immunity. Rev. Infect. Dis. 10(Suppl. 2):S432BS435.
206. Murphy, J. W. 1989. Clearance of Cryptococcus neoformans from immunologically suppressed mice. Infect. Immun. 57:19461952.
207. Murphy, J. W. 1992. Cryptococcal immunity and immunostimulation. Adv. Exp. Med. Biol. 319:225230.
208. Murphy, J. W.,, and R. A. Cox. 1988. Induction of antigen-specific suppression by circulating Cryptococcus neoformans antigen Clin. Exp. Immunol 73:174180.
209. Murphy, J. W.,, and G. C. Cozad. 1972. Immunological unresponsiveness induced by cryptococcal polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5:896901.
210. Murphy, J. W.,, and J. W. Moorhead. 1982. Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J. Immunol. 126:276283.
211. Murphy, J. W.,, and R. L. Mosley. 1985. Regulation of cell-mediated immunity in cryptococcosis. III. Characterization of second-order T suppressor cells (Ts2). J. Immunol. 134:577583.
212. Murphy, J. W.,, R. L. Mosley,, and J. W. Moorhead. 1983. Regulation of cell- immunity in cryptococcosis. II. Characterization of first-order T suppressor cells (Tsl) and induction of second-order suppressor cells. J. Immunol. 30:28762880.
213. Narisawa, Y.,, T. Kojima,, A. Iriki,, J. Masaki,, and H. Kohda. 1986. Tissue changes in cryptococcosis: histologic alteration from gelatinous to suppurative granulomatous tissue response with asteroid body. Mycopathologia 126:6573.
214. Naslund, R K.,, W. C. Miller,, and D. L. Granger. 1995. Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect. Immun. 63:12981304.
215. Nathan, C. 1992. Nitric oxide as a secretary product of mammalian cells. FASEB J. 6:30513064.
216. Nathan, C. E.,, and J. B. Hibbs, Jr. 1991. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3:6570.
217. Neilson, J. B.,, R. A. Fromtling,, and G. S. Bulmer. 1981. Pseudohyphal forms of Cryptococcus neoformans: decreased survival in vivo. Mycopathologia 73:5759.
218. Nishimura, K.,, and M. Miyaji. 1979. Histopathological studies on experimental cryptococcosis in nude mice. Mycopathologia 68:145153.
219. Noble, R. C.,, and L. F. Fajardo. 1971. Primary cutaneous cryptococcosis: review and morphologic study. Am. J. Clin. Pathol 57:1322.
220. Ostrosky-Zeichner, L.,, J. L. Soto-Hernandez,, A. Angeles-Morales,, F. Teixeira,, C. Nava-Ruiz,, C. Rios,, F. Solis,, and J. Sotelo. 1996. Effects of pentoxifylline or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: evidence of neuroexcitatory pathogenic mechanisms. Antimicrob. Agents Chemother. 40:11941197.
221. Pema, K.,, J. Diaz,, L. G. Guerra,, D. Nabhan,, and A. Verghese. 1994. Disseminated cutaneous cryptococcosis. Comparison of clinical manifestations in the pre-AIDS and AIDS eras. Arch. Intern. Med. 154:10321034.
222. Perfect, J. R.,, and D. T. Durack. 1985. Chemotactic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Sabouraudia 23:3745.
223. Perfect, J. R.,, D. T. Durack,, and H. A. Gallis. 1983. Cryptococcemia. Medicine 62:98109.
224. Perfect, J. R.,, D. L. Granger,, and D. T. Durack. 1987. Effects of antifungal agents and gamma-interferon on macrophage cytotoxicity for fungi and tumor cells. J. Infect. Dis. 156:316323.
225. Perfect, J. R.,, S. D. R. Lang,, and D. T. Durack. 1980. Chronic cryptococcal meningitis. Am. J. Pathol. 101:177193.
226. Pettoello-Mantovani, M.,, A. Casadevall,, and H. Goldstein. 1992. The presence of cryptococcal capsular polysaccharide increases the sensitivity of HIV-1 coculture in children. In Proc. Pediatric AIDS: Clinical, Pathologic and Basic Science Perspectives, Washington, D.C. (Abstract.)
227. Pettoello-Mantovani, M.,, A. Casadevall,, and H. Goldstein. 1993. The presence of cryptococcal capsular polysaccharide increases the sensitivity of HIV-1 coculture in children. Ann. NY. Acad. Sci. 693:281283.
228. Pettoello-Mantovani, M.,, A. Casadevall,, T. R. Kollman,, A. Rubinstein,, and H. Goldstein. 1992. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 339:2123.
229. Pettoello-Mantovani, M.,, A. Casadevall,, P. Smarnworawong,, and H. Goldstein. 1994. HIV-1 infectivity is increased in vitro by the presence of the capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae. AIDS Res. Hum. Retroviruses 10:10791087.
230. Picon, L.,, L. Vaillant,, T. Duong,, G. Lorette,, Y. Bacq,, J. M. Besnier,, and P. Choutet. 1989. Cutaneous cryptococcosis resembling molluscum contagiosum: a first manifestation of AIDS. Acta Dermatol. Venereol. 69:365367.
231. Porter, K. G.,, D. G. Sinnamon,, and R. R. Gillies. 1977. Cryptococcus neoformans-specific oligoclonal immunoglobulins in the cerebrospinal fluid in cryptococcal meningitis. Lancet i:1262.
232. Procknow, J. J.,, J. R. Benfield,, J. W. Rippon,, C. F. Diener,, and F. L. Archer. 1965. Cryptococcal hepatitis presenting as a surgical emergency. First isolation of Cryptococcus neoformans from point source in Chicago. JAMA 191:9398.
233. Radhakrishnan, V. V.,, A. Mathai,, J. Shanmugham,, and G. J. Mathews. 1982. The role of hyaluronidase in experimental cryptococcal infections. Surg. Neurol. 17:239244.
234. Randall, R. E.,, W. K. Stacy,, E. C. Toone,, G. R. Prout,, G. E. Madge,, H. J. Shadomy,, S. Shadomy,, and J. P. Utz. 1968. Cryptococcal pyelonephritis. N. Engl. J. Med. 27:6065.
235. Rappaport, B. Z.,, and B. Kaplan. 1926. Generalized torula mycosis. Arch. Pathol. 1:720741.
236. Retini, C.,, A. Vecchiarelli,, C. Monari,, C. Tascini,, F. Bistoni,, and T. R. Kozel. 1996. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect. Immun. 64:28972903.
237. Rhodes, J. C. 1985. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. J. Med. Vet. Mycol. 23:225234.
238. Rhodes, J. C.,, L. S. Wicker,, and W. Urba. 1980. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect. Immun. 29:494499.
239. Robinson, B. E.,, N. K. Hall,, G. S. Bulmer,, and R. Blackstock. 1982. Suppression of responses to cryptococcal antigen in murine cryptococcosis. Mycopathologia 80:157163.
240. Rubinstein, H. R.,, C. E. Sotomayor,, L. A. Cervi,, C. M. Riera,, and D. T. Masih. 1993. Modulation of I-A and I-E expression in macrophages by T-suppressor cells induced in Cryptococcus neoformans infected rats. Mycopathologia 123:141148.
241. Sakaguchi, N.,, T. Baba,, M. Fukuzawa,, and S. Ohno. 1993. Ultrastructural study of Cryptococcus neoformans by quick-freezing and deep-etching method. Mycopathologia 121:133141.
242. Salkowski, C.A.,, and E. Balish. 1991. Cutaneous cryptococcosis in athymic and beige-athymic mice. Infect. Immun. 59:17851789.
244. Salyer, W. R.,, and D. C. Salyer. 1974. Pleural involvement in cryptococcosis. Chest 66:139140.
245. Salyer, W. R.,, D. C. Salyer,, and R. D. Baker. 1974. Primary complex of Cryptococcus and pulmonary lymph nodes. J. Infect Dis. 130:7477.
246. Sarosi, G. A.,, P. M. Silberfarb,, and F. E. Tosh. 1971. Cutaneous cryptococcosis: a sentinel of disseminated disease. Arch. Dermatol. 104:13.
247. Schimpff, S. C.,, and J. E. Bennett. 1975. Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J. Allergy Clin. Immunol. 55:430441.
248. Schneerson-Porat, S.,, A. Sharar,, and M. Aronson. 1965. Formation of histiocyte rings in response to Cryptococcus neoformans infection. RES J. Reticuloendothel. Soc. 2:249255.
249. Schupbach, C. W.,, C. E. Wheeler,, R. A. Briggaman,, N. A. Warner,, and E. P. Kanof. 1976. Cutaneous manifestations of disseminated cryptococcosis. Arch. Dermatol. 112:17341740.
250. Schwartz, D. A. 1988. Characterization of the biological activity of Cryptococcus infections in surgical pathology. The budding index and the carminophilic index. Ann. Clin. Lab. Sci. 18:388397.
251. Selby, R. C.,, and N. M. Lopes. 1973. Torulomas (cryptococcal granulomata) of the central nervous system. J. Neurosurg. 38:4046.
252. Sethi, K. K.,, K. Salfelder,, and J. Schwarz. 1965. Experimental cutaneous primary infection with Cryptococcus neoformans (Sanfelice) Vuillemin. Mycopathol. Mycol. Appl. 27:357368.
253. Shadomy, H. J.,, and H. I. Lurie. 1971. Histopathological observations in experimental cryptococcosis caused by hypha-producing strain of Cryptococcus neoformans in mice. Sabouraudia 9:69.
254. Shahar, A.,, Y. Kletter,, and M. Aronson. 1969. Granuloma formation in cryptococcosis. Isr. J. Med. Sci. 5:11641172.
255. Sokolowski, J. W.,, R. F. Schillaci,, and T. E. Motley. 1969. Disseminated cryptococcosis complicating sarcoidosis. Am. Rev. Respir. Dis. 100:717722.
256. Song, M. M. 1971. Experimental cryptococcosis of the skin. Sabouraudia 12:133137.
257. Sotomayor, C.E.,, H. R. Rubinstein,, L. Cervi,, C. M. Riera,, and D. T. Masih. 1989. Immunosuppression in experimental cryptococcosis in rats. Induction of thymic suppressor cells. Mycopathologia 108:510.
258. Sotomayor, C.E.,, H. R. Rubinstein,, L. Cervi,, C. M. Riera,, and D. T. Masih. 1987. Immunosuppression in experimental cryptococcosis in rats. Induction of afferent T suppressor cells to a non-related antigen. J. Med. Vet. Mycol. 25:6775.
259. Sotomayor, C.E.,, H. R. Rubinstein,, L. Cervi,, C. M. Riera,, and D. T. Masih. 1995. Immunosuppression in experimental cryptococcosis: variation of splenic and thymic populations and expression of class II major histocompatibility complex gene products. Clin. Immunol. Immunopathol. 77:1926.
260. Speed, B.,, and D. Dunt. 1995. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin. Infect. Dis. 21:2834.
261. Speed, B. R.,, J. Kaldor,, B. Cairns,, and M. Pegorer. 1995. Serum antibody response to active infection with Cryptococcus neoformans and its varieties in immunocompetent hosts. J. Med. Vet Mycol. 34:187193.
262. Stevens, D. A.,, J. E. Domer,, R. B. Ashman,, R. Blackstock,, and E. Brummer. 1994. Immunomodulation in the mycoses. J. Med. Vet. Mycol. 32(Suppl. l):253265.
263. Sundstrom, J. B.,, and R. Cherniak. 1992. A glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen. Infect Immun. 60:40804087.
264. Sundstrom, J. B.,, and R. Cherniak. 1993. T-cell dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A. Infect Immun. 61:13401345.
265. Swanson, H.,, and W. A. Smith. 1944. Torular granulomas simulating cerebral tumor. Report of two cases. Arch. Neurol. Psychiatr. 51:426431.
266. Tang, T.,, R S. Frenette,, R. O. Hynes,, D. D. Wagner,, and T. N. Mayadas. 1996. Cytokine-induced meningitis is dramatically attenuated in mice deficient in enothelial selectins. J. Clin. Invest. 97:24852490.
267. Taylor, E. R. 1970. Pulmonary cryptococcosis. Analysis of 15 cases from the Columbia area. Ann. Thorac. Surg. 10:309316.
268. Terplan, K. 1948. Pathogenesis of cryptococcic (Torula) meningitis. Am. J. Pathol. 24:711712.
269. Tohyama, M.,, K. Kawakami,, and A. Saito. 1996. Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide. Antimicrob. Agents Chemother. 40:19191923.
270. Torre, D.,, R. Martegani,, F. Speranza,, C. Zeroli,, and G. P. Fiori. 1995. Pulmonary cryptococcosis presenting as pneumothorax in a patient with AIDS. Clin. Infect. Dis. 21:15241525.
271. Truelsen, K.,, T. Young,, and T. R. Kozel. 1992. In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans. Infect. Immun. 60:39373939.
272. Turner, S.H.,, and R. Chemiak,. 1990. Multiplicity in the structure of the glucuronoxylomannan of Cryptococcus neoformans, p.